Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Sun Pharma Advanced Research Co. Ltd. (SPARC) Price & Analysis

SPARC Stock Chart & Stats

₹176.90-₹6.35(-3.47%)
At close: 4:00 PM EDT
INR 180INR 200INR 2203 Aug17 Aug31 Aug15 Sep28 Sep12 Oct26 Oct
Day’s Range
INR 175.40 - INR 183.50
52-Week Range
INR 108.20 - INR 289.00
Previous Close
INR 183.25
Volume
62.44K
Average Volume (3M)
75.39K
Market Cap
INR 57.41B
Enterprise Value
INR 42.77B
Total Cash (Recent Filing)
INR 11.55M
Total Debt (Recent Filing)
INR 0
Price to Earnings (P/E)
3.6
Beta
1.91
Next Earnings
Nov 02, 2026
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

FY2026 Revenue And Profit Rebound

The reported FY2026 rebound materially improves the company’s near-term earnings base and demonstrates that its development activities can generate substantial financial outcomes. If the improvement reflects repeatable monetization rather than a one-off driver, it could support reinvestment in the pipeline and strengthen operating scale.

Improved FY2026 Balance-sheet Capacity

The FY2026 balance sheet indicates more manageable leverage and a stronger capital position than earlier periods. Debt remains a meaningful obligation, but the current relationship between debt, equity, and assets provides greater financial capacity to continue research programs and pursue commercialization opportunities.

Pipeline Monetization Model

A research-led model gives SPARC multiple potential routes to monetize intellectual property without relying solely on large-scale finished-drug sales. Licensing and collaboration structures can provide milestone payments, service income, and future royalties, creating operating leverage if candidates advance successfully.

Bears Say

Persistent Negative Cash Generation

Continued operating and free-cash-flow deficits show that the FY2026 earnings rebound has not translated into internal cash generation. Ongoing cash burn can require additional funding, constrain investment in clinical development, and reduce the company’s ability to absorb delays or weaker monetization outcomes.

Highly Volatile Earnings Trajectory

The extreme change in revenue and profitability makes the current earnings base difficult to assess as a durable trend. Several prior years of losses and negative margins indicate that results may depend heavily on irregular development or monetization events, increasing uncertainty around sustainable operating performance.

History Of Balance-sheet Strain

Periods of negative equity and unstable leverage reveal a history of financial stress despite the improved FY2026 position. This record may limit flexibility if cash burn persists or development programs require more funding, leaving the company more exposed to future financing needs and execution setbacks.

Sun Pharma Advanced Research Co. Ltd. News

SPARC FAQ

What was Sun Pharma Advanced Research Co. Ltd.’s price range in the past 12 months?
Sun Pharma Advanced Research Co. Ltd. lowest stock price was ₹108.20 and its highest was ₹289.00 in the past 12 months.
What is Sun Pharma Advanced Research Co. Ltd.’s market cap?
Sun Pharma Advanced Research Co. Ltd.’s market cap is ₹57.41B.
When is Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Sun Pharma Advanced Research Co. Ltd.’s earnings last quarter?
Sun Pharma Advanced Research Co. Ltd. released its earnings results on Aug 10, 2026. The company reported -₹0.64 earnings per share for the quarter.
Is Sun Pharma Advanced Research Co. Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Sun Pharma Advanced Research Co. Ltd. pay dividends?
Sun Pharma Advanced Research Co. Ltd. does not currently pay dividends.
What is Sun Pharma Advanced Research Co. Ltd.’s EPS estimate?
Sun Pharma Advanced Research Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sun Pharma Advanced Research Co. Ltd. have?
Sun Pharma Advanced Research Co. Ltd. has 324,521,600 shares outstanding.
What happened to Sun Pharma Advanced Research Co. Ltd.’s price movement after its last earnings report?
Sun Pharma Advanced Research Co. Ltd. reported an EPS of -₹0.64 in its last earnings report. Following the earnings report the stock price went down -2.185%.
Which hedge fund is a major shareholder of Sun Pharma Advanced Research Co. Ltd.?
Currently, no hedge funds are holding shares in IN:SPARC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology